Lactobacillus species: Taxonomic complexity and controversial susceptibilities

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S98-S107

  Goldstein, Ellie J C ^a,b   Tyrrell, Kerin L ^a   Citron, Diane M ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lactobacillus acidophilus; Lactobacillus casei; Lactobacillus rhamnosus; Lactobacillus susceptibility; Probiotics

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CEFOXITIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NETILMICIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSUMER; HUMAN; INFECTION PREVENTION; INGESTION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS ANIMALIS; LACTOBACILLUS ANTRUMI; LACTOBACILLUS BREVIS; LACTOBACILLUS CASEI; LACTOBACILLUS CRISPATUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS FERMENTUM; LACTOBACILLUS GASSERI; LACTOBACILLUS INERS; LACTOBACILLUS JENSENII; LACTOBACILLUS MUCOSAE; LACTOBACILLUS ORIS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; LACTOBACILLUS VAGINALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TAXONOMY; BACTEREMIA; BACTERIAL COUNT; CLASSIFICATION; DRUG EFFECTS; FEMALE; FOOD CONTROL; GRAM-POSITIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; FOOD MICROBIOLOGY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PROBIOTICS;

EID: 84928911081     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ072     Document Type: Article

References (45)

1. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol 1993; 75: 95-107.
2. Roos S, Engstrand L, Jonsson H. Lactobacillus gastricus sp. nov., Lactobacillus antri sp. nov., Lactobacillus kalixensis sp. nov. and Lactobacillus ultunensis sp. nov., isolated from human stomach mucosa. Int J Syst Evol Microbiol 2005; 55(Pt 1): 77-82.
3. Jespers V, Menten J, Smet H, et al. Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests. BMC Microbiol 2012; 12: 83.
4. Lievin-Le Moal V, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev 2014; 27: 167-99.
5. Ljungh A, Wadström T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol 2006; 7: 73-89.
6. Simova ED, Beshkova DM, Angelov MP, Dimitrov ZhP. Bacteriocin production by strain Lactobacillus delbrueckii ssp. bulgaricus BB18 during continuous prefermentation of yogurt starter culture and subsequent batch coagulation of milk. J Ind Microbiol Biotechnol 2008; 35: 559-67.
7. Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis 2015; 60(suppl 2): S135-43.
8. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006; 42: e35-44.
9. Wade WG, Kononen E. Propionibacterium, Lactobacillus, Actinomyces and other Non-spore-forming, anaerobic Gram-Positive rods. In: Versalovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML, Warnock DW. Manual of clinical microbiology. 10th ed. Vol. 1. Washington, DC: ASM Press, 2011: 817-33.
10. Chazan B, Raz R, Shental Y, Sprecher H, Colodner R. Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis. Isr Med Assoc J 2008; 10: 164-5.
11. Suárez-García I, Sánchez-García A, Soler L, Malmierca E, Gómez-Cerezo J. Lactobacillus jensenii bacteremia and endocarditis after dilatation and curettage: case report and literature review. Infection 2012; 40: 219-22.
12. Gouriet F, Million M, Henri M, Fournier P-E, Raoult D. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis 2012; 31: 2469-80.
13. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013; 47: 437-9.
14. Chery J, Dvoskin D, Morato FP, Fahoum B. Lactobacillus fermentum, a pathogen in documented cholecystitis. Int J Surg Case Rep 2013; 4: 662-4.
15. Tena D, Martínez NM, Losa C, Fernández C, Medina MJ, Sáez-Nieto JA. Acute acalculous cholecystitis complicated with peritonitis caused by Lactobacillus plantarum. Diagn Microbiol Infect Dis 2013; 76: 510-2.
16. Callaway A, Kostrzewa M, Willershausen B, et al. Identification of Lactobacilli from deep carious lesions by means of species-specific PCR and MALDI-TOF mass spectrometry. Clin Lab 2013; 59: 1373-9.
17. Civen R, Jousimies-Somer H, Marina M, Borenstein L, Shah H, Finegold SM. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis 1995; 20(suppl 2): S224-9.
18. Luong M-L, Sareyyupoglu B, Nguyen MH, et al. Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection? Transpl Infect Dis 2010; 12: 561-4.
19. Nishijima T, Teruya K, Yanase M, Tamori Y, Mezaki K, Oka S. Infectious endocarditis caused by Lactobacillus acidophilus in a patient with mistreated dental caries. Intern Med 2012; 51: 1619-21.
20. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24: 31-40.
21. Fradiani PA, Petrucca A, Ascenzioni F, et al. Endocarditis caused by Lactobacillus jensenii in an immunocompetent patient. J Med Microbiol 2010; 59(Pt 5): 607-9.
22. Franko B, Vaillant M, Recule C, Vautrin E, Brion J-P, Pavese P. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect 2013; 43: 171-3.
23. Robin F, Paillard C, Marchandin H, Demeocq F, Bonnet R, Hennequin C. Lactobacillus rhamnosus meningitis following recurrent episodes of bacteremia in a child undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2010; 48: 4317-9.
24. Greig JR, Eltringham IJ, Birthistle K. Primary peritonitis due to Lactobacillus fermentum. J Infect 1998; 36: 242-3.
25. Neef PA, Polenakovik H, Clarridge JE, Saklayen M, Bogard L, Bernstein JM. Lactobacillus paracasei continuous ambulatory peritoneal dialysisrelated peritonitis and review of the literature. J Clin Microbiol 2003; 41: 2783-4.
26. Klein G, Zill E, Schindler R, Louwers J. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient: organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998; 36: 1781-3.
27. Bennett DM, Shekhel T, Radelet M, Miller MD. Isolated Lactobacillus chronic prosthetic knee infection. Orthopedics 2014; 37: e83-6.
28. Simkins J, Kaltsas A, Currie BP. Investigation of inpatient probiotic use at an academic medical center. Int J Infect Dis 2013; 17: e321-4.
29. Maziade P-J, Andriessen JA, Pereira P, Currie B, Goldstein EJC. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013; 29: 1341-7.
30. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38: 62-9.
31. Gueimonde M, Sanchez B, G de Los Reyes-Gavilán C, Margolles A. Antibiotic resistance in probiotic bacteria. Front Microbiol 2013; 4: 202.
32. Goldstein BP, Candiani G, Arain TM, et al. Antimicrobial activity of MDL 63, 246, a new semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1995; 39: 1580-8.
33. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003; 47: 1968-71.
34. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006; 50: 3507-13.
35. Florez AB, Ladero V, Alvarez-Martin P, Ammor MS, Alvarez MA, Mayo B. Acquired macrolide resistance in the human intestinal strain Lactobacillus rhamnosus E41 associated with a transition mutation in 23S rRNA genes. Int J Antimicrob Agents 2007; 30: 341-4.
36. Nawaz M, Wang J, Zhou A, et al. Characterization and transfer of antibiotic resistance in lactic acid bacteria from fermented food products. Curr Microbiol 2011; 62: 1081-9.
37. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother 2005; 49: 408-13.
38. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010; 54: 1627-32.
39. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez H. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob Agents Chemother 2002; 46: 1136-40.
40. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013; 57: 4872-6.
41. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother 2013; 57: 2401-4.
42. Goldstein EJ, Citron DM, Vreni Merriam C, Warren Y, Tyrrell KL. Comparative in vitro activities of ertapenem (MK-0826) against 1, 001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000; 44: 2389-94.
43. Clinical, Laboratory Standards I. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guidlines-second edition. Clinical and Laboratory Standards Institute document M45-A2. Wayne, PA: CLSI, 2010.
44. Clinical, Laboratory Standards I. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-8th edition. CLSI document M11-A8. Wayne, PA: CLSI, 2012.
45. Mayrhofer S, Zitz U, Birru FH, et al. Comparison of the CLSI guideline and ISO/IDF standard for antimicrobial susceptibility testing of lactobacilli. Microb Drug Resist 2014; 20: 591-603.